AMD
New NICE Age Related Macular Degeneration guidance supports potential cost savings for the NHS
NHS Clinical Commissioners (NHSCC) and The Royal College of Ophthalmologists (RCOphth) welcome the publication today of guidance from the National Institute for Health and Care Excellence (NICE) which we believe can help to secure better value from the significant funds currently being spent on treating wet age related macular degeneration (AMD). In the current NHS
NICE issue consultation on draft guideline on macular degeneration
The National Institute for Health and Care Excellence has opened a consultation for their draft guideline on macular degeneration, closing 24 August 2017 at 17:00. The draft guideline provides advice on the management of people with AMD, including pharmacological and non-pharmacological treatments. It also provides guidance on tools available to diagnose and monitor AMD, and what information and support
Macular Society’s call for more funding of research into macular degeneration
Statement from the Macular Society Charity’s landmark report exposing lack of investment in age-related macular degeneration (AMD) is supported by more than 60 of the UK’s foremost sight researchers, ophthalmologists and institutions – Situation described as ‘urgent’ It is a disease with devastating and far-reaching consequences for both patients and their families, and the number of
NHS Clinical Commissioners co-ordinate support from CCGs to review use of Avastin to treat wet AMD
College Statement In response to the public letters sent by the NHS Clinical Commissioners to Secretary of State for Health, cc. Chair of NICE; Simon Stevens at NHS England; and the Chair of the GMC and signed by the Clinical Chair / Lead Clinician of 120 CCGs regarding the use of Avastin to treat wet AMD. The Royal
Use of Avastin (bevacizumab) in age related macular degeneration
Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no